[artículo]
| Título : |
A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine xr) monotherapy in patients with generalized anxiety disorder |
| Tipo de documento: |
texto impreso |
| Autores: |
Arifulla Khan, Autor ; Mark Joyce, Autor ; Sarah Atkinson, Autor |
| Fecha de publicación: |
2022 |
| Artículo en la página: |
PP. 418-428 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Palabras clave: |
Agentes ansiolíticos, Agentes antipsicóticos, Ensayo clínico, Fumarato de quetiapina de liberación prolongada, Placebo, Multicéntrico, Estudio de fase 3 |
| Resumen: |
This study evaluated once-daily, extended-release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder (GAD). This was a 10-week (8-week active treatment/2-week posttreatment drug-discontinuation/tapering phase), double-blind, randomized, placebo-controlled study (D1448C00009). Primary end point was change from randomization at week 8 in Hamilton Anxiety Rating Scale (HAM-A) total score. |
| Link: |
./index.php?lvl=notice_display&id=29360 |
in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 4 (Agosto) . - PP. 418-428
[artículo] A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine xr) monotherapy in patients with generalized anxiety disorder [texto impreso] / Arifulla Khan, Autor ; Mark Joyce, Autor ; Sarah Atkinson, Autor . - 2022 . - PP. 418-428. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 4 (Agosto) . - PP. 418-428
| Palabras clave: |
Agentes ansiolíticos, Agentes antipsicóticos, Ensayo clínico, Fumarato de quetiapina de liberación prolongada, Placebo, Multicéntrico, Estudio de fase 3 |
| Resumen: |
This study evaluated once-daily, extended-release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder (GAD). This was a 10-week (8-week active treatment/2-week posttreatment drug-discontinuation/tapering phase), double-blind, randomized, placebo-controlled study (D1448C00009). Primary end point was change from randomization at week 8 in Hamilton Anxiety Rating Scale (HAM-A) total score. |
| Link: |
./index.php?lvl=notice_display&id=29360 |
|
A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine xr) monotherapy in patients with generalized anxiety disorder en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 4 (Agosto)
